Oxycodone extended-release/abuse-resistant - Collegium Pharmaceutical

Drug Profile

Oxycodone extended-release/abuse-resistant - Collegium Pharmaceutical

Alternative Names: COL-003; Oxycodone abuse resistant - Collegium Pharmaceutical; Oxycodone DETERx®; Oxycodone DETERx®ER; Oxycodone DETERx®extended-release; Oxycodone extended release - Collegium pharmaceutical; XTAMPZA ER

Latest Information Update: 10 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Collegium Pharmaceutical
  • Class Alkaloids; Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pain

Most Recent Events

  • 07 Nov 2017 The US FDA approves sNDA to enhance the label of oxycodone extended-release/abuse-resistant (Xtampza® ER) for Pain in USA
  • 06 Nov 2017 The US FDA will not be able to meet the set PDUFA date for sNDA for label update
  • 09 Aug 2017 Collegium Pharmaceutical has patent protection for extended release oxycodone in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top